Tag
PHH-1V, a protein-based COVID-19 vaccine, is shown to be a safe and effective heterologous booster in adolescents, generating strong and lasting immune responses against multiple virus variants.
A large U.S. Veterans Affairs study found no increased 90-day risk of adverse events after same-day COVID-19 and influenza vaccination compared to influenza vaccination alone, supporting the safety of coadministration with updated COVID-19
In over 1 million US veterans, the 2024-2025 COVID-19 vaccine was associated with fewer COVID-19-related cardiovascular events, with the strongest benefit in adults over 75 and those with comorbidities.
A systematic review supports the continued safety and effectiveness of Covid-19, RSV, and influenza vaccines for the upcoming 2025-2026 season, highlighting detailed vaccine efficacy, safety profiles, and recommendations for at-risk populat
The American Academy of Pediatrics recommends COVID-19 vaccination for all young children aged 6-23 months, diverging from current CDC policies that advise shared decision-making for healthy children. This review analyzes epidemiologic data
